5 results on '"Gavra I"'
Search Results
2. Development of a Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease Prediction in UK Biobank.
- Author
-
Giardoglou P, Gavra I, Amanatidou AI, Kalafati IP, Symianakis P, Kafyra M, Moulos P, and Dedoussis GV
- Subjects
- Humans, United Kingdom epidemiology, Male, Female, Middle Aged, Genome-Wide Association Study methods, Genetic Predisposition to Disease, Magnetic Resonance Imaging methods, Aged, Risk Factors, Adult, Genetic Risk Score, UK Biobank, Multifactorial Inheritance genetics, Polymorphism, Single Nucleotide, Biological Specimen Banks, Non-alcoholic Fatty Liver Disease genetics, Non-alcoholic Fatty Liver Disease pathology
- Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of liver-related morbidity and mortality. Although the invasive liver biopsy remains the golden standard for MASLD diagnosis, Magnetic Resonance Imaging-derived Proton Density Fat Fraction (MRI-PDFF) is an accurate, non-invasive method for the assessment of treatment response. This study aimed at developing a Polygenic Risk Score (PRS) to improve MRI-PDFF prediction using UK Biobank data to assess an individual's genetic liability to MASLD., Methods: We iteratively sequestered 10% of MRI-PDFF samples as a validation set and split the rest of each dataset into base and target partitions, containing GWAS summary statistics and raw genotype data, respectively. PRSice2 was deployed to derive PRS candidates. Based on the frequency of SNP appearances along the PRS candidates, we generated different SNP sets according to variable frequency cutoffs. By applying the PRSs to the validation set, we identified the optimal SNP set, which was then applied to a Greek nonalcoholic fatty liver disease (NAFLD) study., Results: Data from 3553 UK Biobank participants yielded 49 different SNP sets. After calculating the PRS on the validation set for every SNP set, an optimal PRS with 75 SNPs was selected (incremental R
2 = 0.025, p -value = 0.00145). Interestingly, 43 SNPs were successfully mapped to MASLD-related known genes. The selected PRS could predict traits, like LDL cholesterol and diastolic blood pressure in the UK Biobank, as also disease outcome in the Greek NAFLD study., Conclusions: Our findings provide strong evidence that PRS is a powerful prediction model for MASLD, while it can also be applied on populations of different ethnicity.- Published
- 2024
- Full Text
- View/download PDF
3. Associations of VEGF-A-Related Variants with Adolescent Cardiometabolic and Dietary Parameters.
- Author
-
Kafyra M, Kalafati IP, Gavra I, Siest S, and Dedoussis GV
- Subjects
- Humans, Adolescent, Cross-Sectional Studies, Diet, Risk Factors, Vascular Endothelial Growth Factor A genetics, Cardiovascular Diseases genetics
- Abstract
Previous research has allowed the identification of variants related to the vascular endothelial growth factor-A (VEGF-A) and their association with anthropometric, lipidemic and glycemic indices. The present study examined potential relations between key VEGF-A-related single-nucleotide polymorphisms (SNPs), cardiometabolic parameters and dietary habits in an adolescent cohort. Cross-sectional analyses were conducted using baseline data from 766 participants of the Greek TEENAGE study. Eleven VEGF-A-related SNPs were examined for associations with cardiometabolic indices through multivariate linear regressions after adjusting for confounding factors. A 9-SNP unweighted genetic risk score (uGRS) for increased VEGF-A levels was constructed to examine associations and the effect of its interactions with previously extracted dietary patterns for the cohort. Two variants (rs4416670, rs7043199) displayed significant associations ( p -values < 0.005) with the logarithms of systolic and diastolic blood pressure (logSBP and logDBP). The uGRS was significantly associated with higher values of the logarithm of Body Mass Index (logBMI) and logSBP ( p -values < 0.05). Interactions between the uGRS and specific dietary patterns were related to higher logDBP and logGlucose ( p -values < 0.01). The present analyses constitute the first-ever attempt to investigate the influence of VEGF-A-related variants on teenage cardiometabolic determinants, unveiling several associations and the modifying effect of diet.
- Published
- 2023
- Full Text
- View/download PDF
4. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera.
- Author
-
Tzartos SJ, Bitzopoulou K, Gavra I, Kordas G, Jacobson L, Kostelidou K, Lagoumintzis G, Lazos O, Poulas K, Sideris S, Sotiriadis A, Trakas N, and Zisimopoulou P
- Subjects
- Animals, Autoantibodies isolation & purification, Escherichia coli genetics, Escherichia coli metabolism, Humans, Immunosuppressive Agents therapeutic use, Mutation genetics, Myasthenia Gravis drug therapy, Myasthenia Gravis genetics, Protein Subunits genetics, Protein Subunits metabolism, Receptors, Cholinergic genetics, Receptors, Cholinergic metabolism, Antigens immunology, Autoantibodies blood, Autoantibodies immunology, Myasthenia Gravis blood, Myasthenia Gravis immunology
- Abstract
Myasthenia gravis (MG) is usually caused by autoantibodies against muscle nicotinic acetylcholine receptor (AChR), which is composed of five subunits (alpha(2)betagammadelta or alpha(2)betaepsilondelta). Current treatments, including plasmapheresis, are nonspecific, causing several side effects. We aim to develop an antigen-specific alternative to plasmapheresis, since the latter removes indispensable plasma components in addition to anti-AChR antibodies. We are developing a method for the selective depletion of the anti-AChR autoantibodies from patients' plasma through the construction of "immunoadsorbent" columns carrying AChR domains. We have expressed the extracellular domains (ECDs, amino acids approximately 1-210/220) of all human muscle AChR subunits in Pichia pastoris and, in preliminary experiments, in E. coli. The ECDs were immobilized (individually or mixed) on Sepharose beads, producing Sepharose-ECD columns, which were tested for their immunoadsorbing capacity on MG sera and shown to specifically eliminate major autoantibody fractions from several MG sera. The immobilized ECDs remained stable and did not dissociate from their matrix after incubation with serum, whereas the procedure was neither toxic nor immunogenic in two experimental rabbits. Testing the intact or antibody-depleted MG sera and the affinity purified autoantibodies showed that both the intact sera and the purified autoantibodies, but not the antibody-depleted sera, could induce AChR loss in cell cultures and experimental MG in rats. This preliminary study suggests that the myasthenic potency of MG sera is entirely due to their anti-AChR antibodies and therefore their depletion should be of therapeutic value. We conclude that ECD-mediated immunoadsorption can be used as an efficient, antigen-specific therapy for MG.
- Published
- 2008
- Full Text
- View/download PDF
5. Expression and characterization of soluble forms of the extracellular domains of the beta, gamma and epsilon subunits of the human muscle acetylcholine receptor.
- Author
-
Kostelidou K, Trakas N, Zouridakis M, Bitzopoulou K, Sotiriadis A, Gavra I, and Tzartos SJ
- Subjects
- Antibodies, Monoclonal metabolism, Base Sequence, Chromatography, Gel, Chromatography, Liquid, Circular Dichroism, Cloning, Molecular, DNA Primers, Enzyme-Linked Immunosorbent Assay, Glycosylation, Humans, Polymerase Chain Reaction, Radioimmunoassay, Receptors, Cholinergic chemistry, Solubility, Muscles metabolism, Receptors, Cholinergic metabolism
- Abstract
The nicotinic acetylcholine receptor (AChR) is a ligand-gated ion channel found in muscles and neurons. Muscle AChR, formed by five homologous subunits (alpha2 beta gamma delta or alpha2 beta gamma epsilon), is the major antigen in the autoimmune disease, myasthenia gravis (MG), in which pathogenic autoantibodies bind to, and inactivate, the AChR. The extracellular domain (ECD) of the human muscle alpha subunit has been heterologously expressed and extensively studied. Our aim was to obtain satisfactory amounts of the ECDs of the non-alpha subunits of human muscle AChR for use as starting material for the determination of the 3D structure of the receptor ECDs and for the characterization of the specificities of antibodies in sera from patients with MG. We expressed the N-terminal ECDs of the beta (amino acids 1-221; beta1-221), gamma (amino acids 1-218; gamma1-218), and epsilon (amino acids 1-219; epsilon1-219) subunits of human muscle AChR in the yeast, Pichia pastoris. beta1-221 was expressed at approximately 2 mg.L(-1) culture, whereas gamma1-218 and epsilon1-219 were expressed at 0.3-0.8 mg.L(-1) culture. All three recombinant polypeptides were glycosylated and soluble; beta1-221 was mainly in an apparently dimeric form, whereas gamma1-218 and epsilon1-219 formed soluble oligomers. CD studies of beta1-221 suggested that it has considerable beta-sheet secondary structure with a proportion of alpha-helix. Conformation-dependent mAbs against the ECDs of the beta or gamma subunits specifically recognized beta1-221 or gamma1-218, respectively, and polyclonal rabbit antiserum raised against purified beta1-221 bound to (125)I-labeled alpha-bungarotoxin-labeled human AChR. Moreover, immobilization of each ECD on Sepharose beads and incubation of the ECD-Sepharose matrices with MG sera caused a significant reduction in the concentrations of autoantibodies in the sera, showing specific binding to the recombinant ECDs. These results suggest that the expressed proteins present some near-native conformational features and are thus suitable for our purposes.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.